Literature DB >> 24843735

Age-associated changes of islet endocrine cells and the effects of body mass index in Japanese.

Hiroki Mizukami1, Kazunori Takahashi1, Wataru Inaba1, Sho Osonoi1, Kosuke Kamata1, Kentaro Tsuboi1, Soroku Yagihashi1.   

Abstract

AIMS/
INTRODUCTION: Impaired growth and premature death of β-cells are implicated in the progression of islet pathology in type 2 diabetes. It remains unclear, however, how aging affects islet cells, or whether the islet change in diabetes is an augmented process of aging. We studied age-related changes of the islet structure in Japanese non-diabetic subjects and explored the underlying mechanism of the changes.
MATERIALS AND METHODS: A total of 115 non-diabetic autopsy cases were subjected to morphometric analysis for volume densities of islets, β- and non-β-cells, as well as their masses. Proliferation activity identified by Ki67, and expressions of pancreatic and duodenal homeobox (PDX)-1, cell cycle inhibitor P16, and oxidative stress marker γH2AX were also examined.
RESULTS: There was a gradual and marginal decline of volume densities of islets, β- and non-β-cells with aging, while masses of these components were increased during maturation and slowly decreased after the 40s. Islet density was high in the young, but reduced after maturation. There was only a minimal influence of increased body mass index (BMI) on the increase in β-cell mass, but not on the other variables. Ki67 positivity and PDX-1 expressions were high in the young, but low after maturation, whereas expressions of P16 and γH2AX were elevated in the aged.
CONCLUSIONS: Age-associated decline of β-cell mass is marginal after maturation, and the reduction of β-cell mass could be a specific process in diabetes. The impact of BMI on the islet structure is limited in Japanese with normal glucose tolerance.

Entities:  

Keywords:  Aging; Islet structure; β‐Cell turnover

Year:  2013        PMID: 24843735      PMCID: PMC4025233          DOI: 10.1111/jdi.12118

Source DB:  PubMed          Journal:  J Diabetes Investig        ISSN: 2040-1116            Impact factor:   4.232


Introduction

Type 2 diabetes has become a recent epidemic. With prolongation of life expectancy, the prevalence of diabetes is increased with aging1. Recent studies disclosed selective reduction of β‐cell mass or its volume density in type 2 diabetic patients and subjects with impaired fasting glucose3. Thus, there is a progressive decline of β‐cells during development of type 2 diabetes. Nevertheless, the question why aging is associated with an increased incidence of diabetes is not fully answered. Whether the β‐cell decrease in older diabetic patients is ascribed to increased insulin resistance in peripheral tissues or direct gluco‐ or lipotoxicity to senescent β‐cells is not clear. It could also be speculated that the aged β‐cells become more fragile to environmental insults, resulting in premature death. The phenotypic alterations of islet endocrine cells with aging are, however, yet to be addressed. In previous studies, β‐cell mass was shown to increase until young adulthood7, and gradually decreased thereafter6. It was recently found that obesity was associated with expansion of the β‐cell mass4. It is still open to question, however, whether the change in obesity is dependent on the increased pancreas volume or reflection of compensatory hyperplasia related to insulin resistance. Butler et al.4 found more robust β‐cell depletion in obese diabetic patients than lean diabetic patients when compared with respective weight‐matched non‐diabetic subjects. The reason for the difference in the extent of β‐cell loss between obese and lean diabetic patients was not well explained in that study. There is a possibility that the plasticity of β‐cells or genesis of diabetes is different between obese and lean subjects. Alternatively, other factors, such as ethnicity or lifestyle, could be involved in β‐cell dynamic changes. As the average body mass index (BMI) of Japanese type 2 diabetes (22–25) is much different from that of American or European diabetic patients (mostly >30), information on the changes of β‐cells in Japanese subjects is valuable for comparison with Westerners. There is an increasing demand to know the value of islet or β‐cell mass for the prediction of diabetes severity and for the validation of new diabetes treatment. To this end, body imaging of the islet is also being explored10. Consequently, background data on the islet distribution, its density, size, endocrine cell turnover, and proliferation capacity are essential to the comparison between diabetes and their controls. In the present study, we therefore carried out precise morphometric analysis on the islet structure with special interest in the effect of aging and BMI, and explored the phenotypic differences in the islets between young and old subjects.

Materials and Methods

Participants

A total of 115 non‐diabetic subjects were collected and the pancreatic specimens were obtained from the subjects who did not have an apparent history of diabetes themselves, or their family history, or previous evidence of hyperglycemia (Table S1). The cases with a history of parenteral alimentation or continuous therapies with potential influences on glucose intolerance, such as steroid or cyclosporine, were also excluded. For inclusion in the present study, the cases were required to have: (i) had a full autopsy within 5 h of death; and (ii) pancreatic tissues stored at full size and a good quality. The samples with lesions of strong inflammation of acute pancreatitis or neoplasms were excluded. Samples undergoing autolysis were also excluded. The use of paraffin blocks was approved by the ethics committee of the Hirosaki University Graduate School of Medicine, and the study conforms to the provision of the Declaration of Helsinki.

Pathological and Immunohistochemical Evaluation

After resection, the pancreas was carefully trimmed of adherent fat and mesenchymal tissue, and weighed. Entire blocks of the body and the tail were fixed in 4% formaldehyde solution, and embedded in paraffin. From the paraffin blocks, several consecutive cross 5‐μm thick sections were obtained. The first section was stained with hematoxylin–eosin (HE) to assess the quality or integrity of the pancreatic tissue. The following serial sections were immunostained by classical streptavidin–biotin–peroxidase system (Nichirei Co., Tokyo, Japan), first incubated overnight at 4°C with monoclonal antibody to chromogranin A (1:1000; Dako Cytomation, Glostrup, Denmark) for the determination of islet volume density, monoclonal anti‐insulin antibody (1:2000; Santa Cruz Biotech, Inc., Santa Cruz, CA, USA) for volume density of β‐cells, and cocktail polyantibodies of glucagon (1:3000; Dako), somatostatin (1:2000; Dako) and pancreatic polypeptide (1:3000; Life Tech. Corp., Carlsbad, CA, USA) for volume density of non‐β‐cells. The sections were lightly counterstained with nuclear hematoxylin to count the number of nuclei of endocrine cells. To explore cell death, proliferation rate, insulin synthetic activity or cellular senescence, double immunostainings with anti‐insulin with terminal deoxynucleotidyl transferase dUTP nick endlabeling (TUNEL) of an ApopTag® (Millipore, Bellerica, MA, USA), Ki67 (MIB1) (1:2500; Dako), β‐cell transcription factor (pancreatic and duodenal homeobox 1 (PDX‐1), 1:2500, EPR3358; Epitomics, Burlingame, CA, USA)12, or cyclin‐dependent kinase inhibitor P16 (1:500, F‐12; Santa Cruz)14 were carried out, respectively. To estimate the degree of oxidative stress‐related cell damage as a sign of preapoptotic state, the expression of immunoreactive γH2AX (Ser139, 1:100, JBW301; Millipore)16 were examined. Briefly, the sections were first incubated with TUNEL agents (ApopTag®) or antibodies against Ki67, PDX‐1, P16, H2AX and then antibody to insulin. After incubation with secondary antibody and enhancing agents, the reaction products were visualized with diaminobenzidine18.

Morphometric Analysis

For determination of islet area, the fractional β‐cell area and non‐β‐cell area, the entire pancreatic sections were imaged at ×5 and ×40 magnification (×4 objective), respectively. The ratio of the islet area (islet volume density [Vi]), β‐cell area (β‐cell volume density [Vβ]) and non‐β‐cell area (volume density of non‐β‐cell [Vnβ]) to total parenchymal area including exocrine pancreas, interstitial stromal and fatty tissues was digitally quantified at a point count basis as previously described using Image J (version 1.56; NIH, Bethesda, MD, USA)18. The masses of islets (Mi), β‐cell (Mβ) and non‐β‐cell (Mnβ) were obtained by multiplication of Vi, Vβ, and Vnβ by pancreas weight. The islet density per unit area (population of the islet) was obtained by division of the number of chromogranin A‐positive area by total parenchymal area. Average islet size and β‐cell size were obtained by division of the total islet area or β‐cell area by the number of islets or the number of β‐cells, respectively9. To determine β‐cell growth, double‐positive cells with insulin and Ki67 (among over 2,000 β‐cells) in all the islets in the section were examined, and the number of Ki67‐positive cells expressed in terms of cells per respective β‐cells. For determination of apoptotic cells, we used slides double‐stained for insulin and TUNEL. As apoptotic cells were rarely found, we did not quantify the number because of unfeasibility to statistics. Intensities of immunoreactions of PDX‐1, P16 and γH2AX were semiquantified in each case using at least 100 islets larger than 200 μm in size. Each islet's reaction was determined to be negative (no reaction), 1+ positive (weakly positive with negative reaction in exocrine areas), 2+ (clearly positive) and 3+ (strongly positive). Average scores represented the value of individual subjects.

Statistical Analysis

Data are presented as mean ± standard error of the mean. Statistical comparisons were carried out using one‐way anova with Bonnferroni post‐hoc corrections. A simple regression was carried out for the correlation analysis. P‐values <0.05 were taken as significant (StatView version 5.0.1; SAS Institute, Mountain View, CA, USA).

Results

Subject Demography

A total of 115 cases (49 male, 66 female) among 670 autopsy cases procured from our autopsy files at Hirosaki University Hospital, Hirosaki, Japan, and related hospitals fulfilled our inclusion criteria. Other cases excluded were late autopsies showing autolysis, signs of pancreatitis, history of diabetes, glucose intolerance, steroid use, parenteral alimentation or cachexia as a result of malignancy (Table S1). The number of cases in each decade of age was 11 in 0–9 years, 17 in 10–19 years, 22 in 20–29 years, ten in 30–39 years, 21 in 40–49 years, ten in 50–59 years, 16 in 60–69 years and eight in 70–79 years. The average age was 58 years in males and 59 years in females. Original diseases were cardiovascular, liver, digestive diseases, amyloidosis, renal disease and psychiatric disorders. BMI was increased with maturation and reduced after 60 year‐of‐age. Average BMI was 13.7 until 20 years‐of‐age, and 24.6 in the 40s and 50s. The overall average BMI was 20.0 ± 3.8. As the BMI values were much lower in the young than those in the adults and aged, the effects of BMI on the morphometric parameters of the islets were evaluated in the subjects aged more than 20 years in the following text. The mean pancreas weight rapidly increased until the third decade of life (Figure 1a). Thereafter, it was constant until the 50s, and then slightly reduced in the 60s and 70s. There was a strong correlation of increased pancreas weight with BMI (r = 0.46, P < 0.001; Figure 1b).
Figure 1

Age‐related changes of pancreas weight and the effect of body mass index (BMI) on the weight. (a) Pancreas weight increases with maturation until the third decade of life and remains constant until the 50s. Thereafter, the weight decreases slightly (P < 0.01 vs 10–70). (b) With increasing BMI, pancreas weight also increases. There is a strong correlation between pancreas weight and BMI. (c) By morphometric analysis, average volume densities of islets (Vi), β‐cells (Vβ) and non‐β‐cells (Vnβ) in each decade of life are shown. Islet volume density (Vi) of the first decade of life is significantly greater compared with those in later life (*P < 0.05), suggesting late development of the exocrine pancreas. Thereafter, Vi is preserved, but slowly and minimally declines with aging (see also Figure S2). Similarly, Vβ gradually and marginally decreases with aging, but is relatively well preserved (†P < 0.05 vs first and second decade). In the young, Vnβ is relatively greater compared with those aged older than 10 years (§P < 0.01 vs 10–79). (d) In contrast to volume density, total islet mass (Mi) increases with maturation until the 30s, and thereafter gradually decreases (#P < 0.01 vs 10–59, P < 0.05 vs 60–79). The peak was found from the 20s to the 50s. β‐Cell mass (Mβ) also increases with maturation until the 20s, and is thereafter maintained until the 50s and then gradually declines, but is still preserved (**P < 0.01 vs 10–69, P < 0.05 vs 70–79). Non‐β‐cell mass (Mnβ) also increases with maturation, but slightly later than β‐cells and after the 50s it declines slightly (††P < 0.01 vs 20–50 years, §§P < 0.01 vs 30 years, P < 0.05 vs 40–50 years, ##P < 0.05 vs 30–49 years and 70–79 years, ***P < 0.01 vs 30–39 years, P < 0.05 vs 40–59 years).

Age‐related changes of pancreas weight and the effect of body mass index (BMI) on the weight. (a) Pancreas weight increases with maturation until the third decade of life and remains constant until the 50s. Thereafter, the weight decreases slightly (P < 0.01 vs 10–70). (b) With increasing BMI, pancreas weight also increases. There is a strong correlation between pancreas weight and BMI. (c) By morphometric analysis, average volume densities of islets (Vi), β‐cells (Vβ) and non‐β‐cells (Vnβ) in each decade of life are shown. Islet volume density (Vi) of the first decade of life is significantly greater compared with those in later life (*P < 0.05), suggesting late development of the exocrine pancreas. Thereafter, Vi is preserved, but slowly and minimally declines with aging (see also Figure S2). Similarly, Vβ gradually and marginally decreases with aging, but is relatively well preserved (†P < 0.05 vs first and second decade). In the young, Vnβ is relatively greater compared with those aged older than 10 years (§P < 0.01 vs 10–79). (d) In contrast to volume density, total islet mass (Mi) increases with maturation until the 30s, and thereafter gradually decreases (#P < 0.01 vs 10–59, P < 0.05 vs 60–79). The peak was found from the 20s to the 50s. β‐Cell mass (Mβ) also increases with maturation until the 20s, and is thereafter maintained until the 50s and then gradually declines, but is still preserved (**P < 0.01 vs 10–69, P < 0.05 vs 70–79). Non‐β‐cell mass (Mnβ) also increases with maturation, but slightly later than β‐cells and after the 50s it declines slightly (††P < 0.01 vs 20–50 years, §§P < 0.01 vs 30 years, P < 0.05 vs 40–50 years, ##P < 0.05 vs 30–49 years and 70–79 years, ***P < 0.01 vs 30–39 years, P < 0.05 vs 40–59 years). Although small to large islets were randomly and densely distributed in pancreatic parenchyma where the exocrine pancreas was not fully developed in the young, large and relatively uniform islets were sparsely distributed in the adult pancreas (Figure S1). Vi was markedly high in the first decade, and there was a mild and gradual decline of Vi with aging (Figure 1c). This alteration was in parallel with the age‐associated changes of Vnβ. Vβ also slowly and progressively declined with aging, and reduction was marked in the 70s. Correlation analysis confirmed statistical significance (Figure S2). Mi and Mnβ were stepwisely increased until the fourth decade of life, and then there appeared to show a gradual decline. Mβ was low in the first decade of life, and rapidly expanded in the second decade and was well preserved thereafter (Figure 1d). The high values of Vi, Vβ and Vnβ in the young reflect the slower development of the exocrine pancreas during maturation. There were no differences in these variables between males and females. Islet density was high in the first decade, but after maturation it was stable (Table 1). Islets composed of less than four cells (small islets termed neogenetic islets) followed a similar trend, whereas large islets were well preserved even in the aged subjects. Conversely, β‐cell occupancy in the islet was low in the first decade, but thereafter constantly exceeded 60%. Average β‐cell size was increased with maturation and further increased with aging. In contrast, β‐cell density was high in the young, and gradually declined with aging. A size frequency histogram of the islets showed left‐sided distribution, indicating a greater population of small islets (<250 μm2) in the young and a gradual reduction of small islets with aging (Figure 2a). Large islets exceeding 10,000 μm2 were most prevalent in the fourth decade. The density of neogenetic islets correlated with Vi (r = 0.27, P < 0.01; Figure 2b).
Table 1

Numerical data of islet density, occupancy of β‐cells in the islet, β‐cell size and β‐cell density

Age (years)0–910–1920–2930–3940–4950–5960–6970–79
Islet density, n (/mm2)9.0 ± 1.6*4.4 ± 0.44.2 ± 0.53.6 ± 0.53.4 ± 0.43.2 ± 0.53.5 ± 0.33.4 ± 0.5
Small islet density (/mm2)5.3 ± 1.3*2.7 ± 0.32.5 ± 0.42.1 ± 0.42.0 ± 0.32.0 ± 0.41.9 ± 0.21.9 ± 0.2
Large islet density (/mm2)3.7 ± 0.6*1.7 ± 0.21.7 ± 0.11.5 ± 0.21.4 ± 0.11.3 ± 0.21.6 ± 0.21.5 ± 0.3
β‐Cell occupancy in islet (%)54.4 ± 3.565.8 ± 3.165.6 ± 1.764.9 ± 2.6**66.0 ± 2.563.1 ± 2.3**63.0 ± 2.1**60.2 ± 3.9
β‐Cell size (μm2)83.3 ± 11.2100.5 ± 7.3111.6 ± 5.8**120.1 ± 6.4**119.4 ± 11.4**125.1 ± 11.1126.0 ± 8.5**129.4 ± 12.0
β‐Cell number (/mm2)152.3 ± 24.8101.2 ± 7.6**91.0 ± 4.483.7 ± 4.386.2 ± 8.885.9 ± 6.882.9 ± 6.779.3 ± 8.9

*P < 0.01 vs 10 –79 years, †P < 0.01 vs 0–9 years, **P < 0.05 vs 0–9 years.

Figure 2

Frequency histogram of the islet size and number, and changes with aging. (a) Small islets (<1,000 μm2) occupy more than 80% of all islets. Larger islets (>10,000 μm2) were relatively marked during the 30s to 40s. Middle‐sized islets (3,000–5,999 μm2) were constant throughout life. In juveniles, most of the islets were small, mainly <2,000 μm2. During maturation, the number of islets per unit area was much reduced until the 20s and remained constant thereafter. With aging, the number of small islets was decreased and there was a gradual increase in larger islets with maturation. (b) The number of small neogenetic islets per unit area is well correlated with islet volume density (Vi).

*P < 0.01 vs 10 –79 years, †P < 0.01 vs 0–9 years, **P < 0.05 vs 0–9 years. Frequency histogram of the islet size and number, and changes with aging. (a) Small islets (<1,000 μm2) occupy more than 80% of all islets. Larger islets (>10,000 μm2) were relatively marked during the 30s to 40s. Middle‐sized islets (3,000–5,999 μm2) were constant throughout life. In juveniles, most of the islets were small, mainly <2,000 μm2. During maturation, the number of islets per unit area was much reduced until the 20s and remained constant thereafter. With aging, the number of small islets was decreased and there was a gradual increase in larger islets with maturation. (b) The number of small neogenetic islets per unit area is well correlated with islet volume density (Vi). In contrast to the positive correlation of pancreas weight with BMI, there was no significant effect of BMI on the value of Vi, Vβ and Vnβ (Figure 3a). Similarly, BMI did not significantly influence the values of Mi, Mβ and Mnβ, despite near significant correlation between BMI and Mβ (r = 0.23, P = 0.056; Figure 3b). The separation of groups into an obese group (BMI ≥ 25) and lean group (BMI < 25) yielded a marginally significant difference in the Mi and Mβ (P < 0.05 for both), but not Vi, Vβ, Vnβ or Mnβ between these two groups (Figure 3c). In addition, there was no significant effect of BMI on the density of neogenetic islets (small islets <4 cells; data not shown).
Figure 3

The relationship between body mass index (BMI) and volume densities of islets (Vi), β‐cells (Vβ) and non‐β‐cells (Vnβ), and their masses (M). (a) There is no significant correlation between BMI and Vi, Vβ or Vnβ. (b) Similarly, BMI does not have a significant impact on the islet mass (Mi), β‐cell mass (Mβ) and non‐β‐cell mass (Mnβ), although the effect on Mβ was nearly significant (P = 0.06). (c) The comparison of volume densities of islets (Vi), β‐cells (Vβ), non‐β‐cells (Vnβ), and masses of islets (Mi), β‐cells (Mβ) and non‐β‐cells (Mnβ) between lean and obese subjects. Lean subjects had a BMI < 25 and obese subjects had a BMI ≥ 25. There were no significant differences in Vi, Vnβ, Vβ and Mnβ, whereas there were marginal but significant increases in Mi and Mβ in obese subjects. *P < 0.05 vs BMI < 25.

The relationship between body mass index (BMI) and volume densities of islets (Vi), β‐cells (Vβ) and non‐β‐cells (Vnβ), and their masses (M). (a) There is no significant correlation between BMI and Vi, Vβ or Vnβ. (b) Similarly, BMI does not have a significant impact on the islet mass (Mi), β‐cell mass (Mβ) and non‐β‐cell mass (Mnβ), although the effect on Mβ was nearly significant (P = 0.06). (c) The comparison of volume densities of islets (Vi), β‐cells (Vβ), non‐β‐cells (Vnβ), and masses of islets (Mi), β‐cells (Mβ) and non‐β‐cells (Mnβ) between lean and obese subjects. Lean subjects had a BMI < 25 and obese subjects had a BMI ≥ 25. There were no significant differences in Vi, Vnβ, Vβ and Mnβ, whereas there were marginal but significant increases in Mi and Mβ in obese subjects. *P < 0.05 vs BMI < 25. During maturation until the late 20s, the Ki67‐positive rate (index) of islet endocrine cells including both β‐ and non‐β‐cells was relatively high (Figure 4a). Proliferation of non‐β‐cells exceeded that of β‐cells in the young. Thereafter, the index of these cells was rapidly decreased to below 0.7%. The levels remained consistently low at 0.2–0.5% thereafter. The Ki67 index correlated with the increases in Vi, Vβ and Vnβ (Figure 4b), and was also associated with increases in Mi, Mβ and Mnβ. There was no significant association, however, between Ki67 index of islet cells, β‐cells or non‐β‐cells and BMI (Figure 4c). Apoptotic cells were rarely found in the islets in all groups, although there were some acinar or stromal cells positive for TUNEL (figure not shown).
Figure 4

Proliferation activity (Ki67 index) of endocrine cells and their changes with aging. (a) During maturation, Ki67 indices of islets, β‐cells and non‐β‐cells are relatively high compared with those in later life. They are negatively correlated with aging. However, if comparison is limited to the subjects aged older than 10 years, the correlation is not significant and the index is consistently low (<0.1%), indicating low replicating activity of islet endocrine cells in the adult pancreas (*P < 0.01 vs 10–79 years, †P < 0.01 vs 20–79 years, §P < 0.05 vs 20–79 years). (b) Ki67 index is positively correlated with volume densities of islet (Vi), β‐cell (Vβ) and non‐β‐cell (Vnβ). (c) Body mass index (BMI) does not influence the values of Ki67 index in β‐cells or non‐β‐cells.

Proliferation activity (Ki67 index) of endocrine cells and their changes with aging. (a) During maturation, Ki67 indices of islets, β‐cells and non‐β‐cells are relatively high compared with those in later life. They are negatively correlated with aging. However, if comparison is limited to the subjects aged older than 10 years, the correlation is not significant and the index is consistently low (<0.1%), indicating low replicating activity of islet endocrine cells in the adult pancreas (*P < 0.01 vs 10–79 years, †P < 0.01 vs 20–79 years, §P < 0.05 vs 20–79 years). (b) Ki67 index is positively correlated with volume densities of islet (Vi), β‐cell (Vβ) and non‐β‐cell (Vnβ). (c) Body mass index (BMI) does not influence the values of Ki67 index in β‐cells or non‐β‐cells. There was strongly positive expression of PDX‐1 in the nuclei of β‐cells in the young (Figure 5a). Ductal cells, scattered other endocrine and exocrine cells were also positive. The reaction of β‐cells appeared to be weakened in the aged. In contrast, P16 expressions, as an inhibitor of cell cycle‐dependent kinase, were equivocal in the nuclei of islet cells in the young, whereas they were clearly positive in the adult or older subjects. Concurrently, γH2AX reactions, as a marker of oxidative stress‐induced DNA damage, were weak in the nuclei of islet cells in the young and middle‐aged adults, whereas they were robust in the aged.
Figure 5

Immunohistochemical expression of pancreatic and duodenal homeobox‐1 (PDX‐1), cyclin‐dependent kinase inhibitor (P16) and oxidative‐stress‐related DNA damage (γH2AX) in the islet and their alterations in aging. (a) PDX‐1 expression is clearly identified in the nuclei of islet β‐cells and intensity is strong in young subjects (upper left panel), whereas reactions in older subjects subsided (upper center and right panels). Some acinar cells and ductular cells are also positively stained. In contrast, P16 expression is not so apparent in the young (middle left), whereas older subjects show stronger reactions in the islets (middle center and right). γH2AX expressions are faint in the young and adult until middle age (lower left and right), but intensified in older subjects (>60 years; lower right). (b) Semiquantification of immunoexpressions of PDX‐1, P16 and γH2AX showed that PDX‐1 expression is greater in the young compared with older subjects. In contrast, P16 expression is low in the young subjects compared with adult and older adult subjects. Expression of γH2AX is increased in aged subjects (*P < 0.01 vs 0–9 years, †P < 0.01 vs 0–59 years).

Immunohistochemical expression of pancreatic and duodenal homeobox‐1 (PDX‐1), cyclin‐dependent kinase inhibitor (P16) and oxidative‐stress‐related DNA damage (γH2AX) in the islet and their alterations in aging. (a) PDX‐1 expression is clearly identified in the nuclei of islet β‐cells and intensity is strong in young subjects (upper left panel), whereas reactions in older subjects subsided (upper center and right panels). Some acinar cells and ductular cells are also positively stained. In contrast, P16 expression is not so apparent in the young (middle left), whereas older subjects show stronger reactions in the islets (middle center and right). γH2AX expressions are faint in the young and adult until middle age (lower left and right), but intensified in older subjects (>60 years; lower right). (b) Semiquantification of immunoexpressions of PDX‐1, P16 and γH2AX showed that PDX‐1 expression is greater in the young compared with older subjects. In contrast, P16 expression is low in the young subjects compared with adult and older adult subjects. Expression of γH2AX is increased in aged subjects (*P < 0.01 vs 0–9 years, †P < 0.01 vs 0–59 years). Semiquantitative analysis showed that the expression of PDX‐1 was marked in the young (<10 years) compared with adults (Figure 5b). The expression was further decreased in older subjects (>60 years). In contrast, the expression of P16 was much lower in the young (<10 years) compared with that in the older groups (>10 years). γH2AX expression was faint in the young and middle‐aged (<59 years), whereas it was enhanced in the aged (>60 years). The scores of PDX‐1 expression correlated with Vβ (Figure S3). In contrast, there was an inverse correlation between P16 expression and Vβ. However, there was no significant correlation between γH2AX expression and Vi.

Discussion

The present study is the first to comprehensively show the age‐associated changes of islet endocrine cells, and provide differences in β‐cell features between young and aged subjects. Our findings are in accord with recent results on the β‐cell expansion with enlargement of islet size and the exocrine pancreas during development after birth until the 20s in American non‐diabetic subjects7. The gradual age‐associated decline of Mβ after adulthood was common in Europeans and Japanese, despite the differences in analytical methods6, but not with Americans9. Indeed, the present study confirmed that the decrease in Mβ after the 60s was minimal, just 0.1–0.2% levels and more than 80% masses were well preserved even in the 70s. The findings could indicate that the 30–50% reduction of Mβ or Vβ that we encountered in type 2 diabetic subjects either in Japan or Western countries is not merely the consequence of enhanced dropout of aged β‐cells, but due to a specific injury to β‐cells as well as poor ability of β‐cell replication3. The mechanism of a gradual decline in Mβ with aging is yet to be made clear, and previous studies have not addressed this issue well. The present study disclosed several possibilities by detection of: (i) a gradual decrease in Ki67 index and PDX‐1 expressions in adults; (ii) an enhanced expression of P16; and (iii) accumulation of γH2AX in the aged. The reduced PDX‐1 expression in aging β‐cells was established in animal models20, and we found it was also the case in humans. As we showed an increased expression of γH2AX in the aged, DNA injury as a result of oxidative stress could interfere with the signals of β‐cell transcription factors, resulting in a lowered expression of PDX‐1. In fact, enhanced oxidative stress is known to promote translocation of PDX‐1 from the nucleus to cytoplasm in rodent islets22. Interestingly, P16 expression was inversely correlated with Ki67 index. Such opposite expression of P16 against PDX‐1 and Ki67 was recently shown in the islets during β‐cell maturation in the prenatal and postnatal human pancreas15. Collectively, it is likely that the gradual decline of Vi or Vβ was a result of the low replicating activity of cells, not by increased apoptosis, as apoptotic β‐cells were hardly detected, as described in the human pancreas3. Nevertheless, the absence of TUNEL‐positive cells might not directly indicate the lack of apoptosis, as the cell cycle of apoptosis is fairly rapid, and the cells undergoing apoptosis can rapidly be phagocytosed. In addition, there might be other mechanisms of β‐cell decline; autophagy deficit24, telomere shortening26, as well as necrosis27. Recent substructural demonstration of lipofuscin accumulation suggested an extremely long lifespan of islet endocrine cells29. In concert with this contention, the present findings of enhanced expression of γH2AX in aged β‐cells could indicate that aged β‐cells are more or less damaged by long‐term exposure to environmental insults and susceptible to cell death. In contrast to previous investigators, who found that Vβ in human obesity was increased by ~50% in American and European subjects4, we could not obtain a significant impact of BMI on Vi or Vβ, but only marginal effects on Mi and Mβ (Figure 3). A comparison between the lean group (BMI < 25) and obese group (BMI ≥ 25) yielded a significant increase only in Mi and Mβ in the latter, but not in Vi or Vβ. Thus, the impact of obesity on the β‐cell mass is not so robust in Japanese people compared with Americans. In addition, there was no significant correlation of BMI with Ki67 index (Figure 4c). Collectively, distinct from Western people, cellular adaptation to obesity or insulin resistance in β‐cells appears to be limited in Japanese non‐diabetic subjects. The reason for this discrepancy is not clear, but the ethnicity or different lifestyles might have yielded the different results. Alternatively, the increase in BMI in Japanese subjects compared with Americans might have been too small to yield an influence of BMI on the islet structure. In fact, an average BMI was much lower, and its range was smaller in Japanese subjects (mean 20.8, range 19–28) than those in Americans (mean 25–26, range 18–42)31. It should be of note, however, that there was a significant correlation of BMI with Vβ even in a small number of Korean subjects (just nine cases)5. The difference between the Korean study and ours could be ascribed to the limited younger autopsy cases and the inclusion of more obese subjects in the Korean study compared with ours. In addition, the difference in cultural habits or diet could have influenced the results among the same Asian people. Notwithstanding, the present results might suggest that diabetes develops differently between obese and lean subjects, as the comparison of reduced Vβ showed a large difference between obese and lean diabetic subjects in one American study4. This contention is purely speculative, however, requiring critical investigation in future. There is a caution that the interpretation of the morphometric data could mislead, because the increased pancreatic weight is affected by fatty changes in obese or aged subjects33. Exclusion of peripancreatic fat tissues infiltrating into pre‐existing exocrine pancreatic parenchyma in obese or aged subjects might erroneously result in a false increase in Vβ and Mβ. Indeed, it is often difficult to make a border of pancreatic parenchyma and quantify the exocrine pancreatic area where fatty tissues are involved in the pancreas of obese or aged subjects. Standardization of morphometric analysis should, therefore, be established for the comparison of the data reported from different institutions. The present study had a number of limitations that could make interpretation difficult. Our data might have been influenced by unavoidable factors encountered at the agonal stage of the patients: circulatory insufficiency, blood pressure changes, rapid glucose imbalance and metabolic catabolism. It was not feasible to find a correlation of blood glucose elevations with the structural data, because of inadequate information at the time of autopsy. We searched the clinical records of the patients extensively and excluded the subjects who had a possibility of glucose intolerance in their clinical history. In a few studies, the use of samples obtained at the time of surgery was attempted5. In such studies, however, there are again factors that might affect the values, such as blood changes or underlying diseases for surgery. β‐Cells are known to respond to environmental factors, resulting in islet hyperplasia in pregnancy35 or gastrectomy37. There is a possibility that we might also have included some cases in which normal age‐associated changes of the islet structure were influenced by hitherto unknown mediators. We hope that a sufficient number of subjects using 115 cases, which is the largest cohort in human islet structural studies, could have reduced the influence of confounding factors in the present study. The main purpose of diabetes treatment has become to prevent a progressive decline of β‐cells and to restore the β‐cell deficit. To this end, development of in vivo imaging of β‐cells to monitor the efficacy of treatment is expected10. The data obtained from the current study can therefore be hoped to serve non‐diabetic standards for the comparison with diabetic subjects. Quantitative analysis on the islet might not be so straightforward because of variation of the data caused by different methodology39. Critical comparison of the data between isolated islets, and freshly obtained sections by immunohistochemistry and ultrastructure found −30 + 23% differences in β‐cell occupancy and size39. Future investigations might be warranted to confirm the data on the age‐associated dynamic changes by addition of molecular and biochemical alterations of the islets. Table S1 | Age distribution and number of cases investigated in each decade and mean body mass index (BMI) Click here for additional data file. Figure S1 | Islet distribution and contour from youth to old age in Japanese non‐diabetic subjects immunostained with chromogranin A Click here for additional data file. Figure S2 | Correlation of analysis on the relationship between age and volume densities of islet (Vi), β‐cell (Vβ) and non‐β‐cell (Vnβ) Click here for additional data file. Figure S3 | Scoring of immunohistochemical expression of pancreatic and duodenal homeobox‐1 (PDX‐1), and P16 and γH2AX and their relationships to β‐cell volume density, and Ki67 index Click here for additional data file.
  41 in total

Review 1.  Epidemiology of type 2 diabetes.

Authors:  Nicholas J Wareham
Journal:  Endocrinol Nutr       Date:  2009-12

2.  Telomere shortening with aging in the human pancreas.

Authors:  Akio Ishii; Ken-Ichi Nakamura; Hiroshi Kishimoto; Naoko Honma; Junko Aida; Motoji Sawabe; Tomio Arai; Mutsunori Fujiwara; Fujio Takeuchi; Motonobu Kato; Mitsuo Oshimura; Naotaka Izumiyama; Kaiyo Takubo
Journal:  Exp Gerontol       Date:  2006-07-24       Impact factor: 4.032

3.  Cell cycle control of β-cell replication in the prenatal and postnatal human pancreas.

Authors:  Christina U Köhler; Marvin Olewinski; Andrea Tannapfel; Wolfgang E Schmidt; Helga Fritsch; Juris J Meier
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-26       Impact factor: 4.310

4.  Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

Authors:  Wataru Inaba; Hiroki Mizukami; Kosuke Kamata; Kazunori Takahashi; Kentaro Tsuboi; Soroku Yagihashi
Journal:  Eur J Pharmacol       Date:  2012-07-20       Impact factor: 4.432

5.  Aging correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1.

Authors:  Kathrin Maedler; Desiree M Schumann; Fabienne Schulthess; José Oberholzer; Domenico Bosco; Thierry Berney; Marc Y Donath
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

6.  Formation of a human β-cell population within pancreatic islets is set early in life.

Authors:  Brigid E Gregg; Patrick C Moore; Damien Demozay; Ben A Hall; Mei Li; Aliya Husain; Amy J Wright; Mark A Atkinson; Christopher J Rhodes
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

7.  Quantitative analysis of cell composition and purity of human pancreatic islet preparations.

Authors:  Anna Pisania; Gordon C Weir; John J O'Neil; Abdulkadir Omer; Vaja Tchipashvili; Ji Lei; Clark K Colton; Susan Bonner-Weir
Journal:  Lab Invest       Date:  2010-08-09       Impact factor: 5.662

Review 8.  Molecular mechanisms and pathophysiology of necrotic cell death.

Authors:  Nele Vanlangenakker; Tom Vanden Berghe; Dmitri V Krysko; Nele Festjens; Peter Vandenabeele
Journal:  Curr Mol Med       Date:  2008-05       Impact factor: 2.222

9.  The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation.

Authors:  M Cnop; S J Hughes; M Igoillo-Esteve; M B Hoppa; F Sayyed; L van de Laar; J H Gunter; E J P de Koning; G V Walls; D W G Gray; P R V Johnson; B C Hansen; J F Morris; M Pipeleers-Marichal; I Cnop; A Clark
Journal:  Diabetologia       Date:  2009-10-24       Impact factor: 10.122

10.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

Authors:  Alexandra E Butler; Juliette Janson; Susan Bonner-Weir; Robert Ritzel; Robert A Rizza; Peter C Butler
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more
  20 in total

Review 1.  Islet biology, the CDKN2A/B locus and type 2 diabetes risk.

Authors:  Yahui Kong; Rohit B Sharma; Benjamin U Nwosu; Laura C Alonso
Journal:  Diabetologia       Date:  2016-05-07       Impact factor: 10.122

Review 2.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

Review 3.  Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine Pancreas.

Authors:  Yoshifumi Saisho
Journal:  Rev Diabet Stud       Date:  2016-08-10

4.  Telomere attrition in beta and alpha cells with age.

Authors:  Yoshiaki Tamura; Naotaka Izumiyama-Shimomura; Yoshiyuki Kimbara; Ken-Ichi Nakamura; Naoshi Ishikawa; Junko Aida; Yuko Chiba; Yoko Matsuda; Seijiro Mori; Tomio Arai; Mutsunori Fujiwara; Steven S S Poon; Tatsuro Ishizaki; Atsushi Araki; Kaiyo Takubo; Hideki Ito
Journal:  Age (Dordr)       Date:  2016-05-24

5.  Pancreatic Pseudoislets: An Organoid Archetype for Metabolism Research.

Authors:  Mollie S H Friedlander; Vy M Nguyen; Seung K Kim; Romina J Bevacqua
Journal:  Diabetes       Date:  2021-05-04       Impact factor: 9.461

Review 6.  The Human Islet: Mini-Organ With Mega-Impact.

Authors:  John T Walker; Diane C Saunders; Marcela Brissova; Alvin C Powers
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 25.261

7.  Age-associated changes of islet endocrine cells and the effects of body mass index in Japanese.

Authors:  Hiroki Mizukami; Kazunori Takahashi; Wataru Inaba; Sho Osonoi; Kosuke Kamata; Kentaro Tsuboi; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2013-08-04       Impact factor: 4.232

8.  Quo vadis: Where have the β-cells gone?

Authors:  Soroku Yagihashi; Hiroki Mizukami; Wataru Inaba
Journal:  J Diabetes Investig       Date:  2014-10-18       Impact factor: 4.232

9.  Islet amyloid with macrophage migration correlates with augmented β-cell deficits in type 2 diabetic patients.

Authors:  Kosuke Kamata; Hiroki Mizukami; Wataru Inaba; Kentaro Tsuboi; Yoshinori Tateishi; Taro Yoshida; Soroku Yagihashi
Journal:  Amyloid       Date:  2014-07-09       Impact factor: 7.141

Review 10.  Dynamic pathology of islet endocrine cells in type 2 diabetes: β-Cell growth, death, regeneration and their clinical implications.

Authors:  Soroku Yagihashi; Wataru Inaba; Hiroki Mizukami
Journal:  J Diabetes Investig       Date:  2015-10-15       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.